Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$25.79 USD
+1.16 (4.71%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $25.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 25.79 +1.16(4.71%)
Will NTLA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Other News for NTLA
3 Best Stocks to Buy Now, 6/28/2024, According to Top Analysts
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Buy Rating for Intellia Therapeutics: Promising Clinical Data and Potential for Redosing in ATTR Amyloidosis
3 Biotech Stocks For The Second Half Of 2024